Medtainer, Inc. Completes Acquisition of Advanced Container Technologies

October 20, 2020

On October 9, 2020, Medtainer, Inc. consummated an exchange agreement with California-based Advanced Container Technologies, Inc. and its shareholders under which these shareholders exchanged their shares in ACT for 50,000,000 shares of Medtainer’s common stock. As a result, ACT has become the wholly-owned subsidiary of Medtainer.

In connection with this transaction, Medtainer, which is a Florida corporation, changed its name to Advanced Container Technologies, Inc., effective October 3, 2020, and its trading symbol to ACTX, effective 20 business days after October 9. On October 8, 2020, the outstanding shares of Medtainer’s common stock were reverse-split on the basis of one new share for every 59 shares outstanding. Medtainer now has 51,001,860 shares outstanding, which are held by 427 shareholders.

On August 6, 2020, ACT and GP Solutions, Inc. (“GP”), of Colton, California, entered into a Distributorship Agreement, under which ACT has the exclusive right to market, sell and distribute GP’s products in the United States and its territories. This agreement has an initial term that expires on December 31, 2025, and is renewable indefinitely as long as ACT meets prescribed sales targets. GP manufactures fully insulated, food-grade shipping containers that are specifically modified to provide an optimal controlled environment for growing a wide range of horticultural and agricultural products in all environments and climates. The containers can be used to grow large amounts products in a small volume and in a short period: for example, according to GP, 4,000 heads of romaine lettuce can be grown in a single container in less than 5 weeks.

Medtainer entered into the exchange agreement because its board of directors believed that the company needed to expand its product base and become profitable. Douglas P. Heldoorn, the chief executive officer of Medtainer and a member of its board of directors, stated: “Our sales have been relatively flat for the past several years and the Company has a history of losses. We are delighted to have acquired ACT and believe that it offers an opportunity to expand our products, enter into a new market and increase shareholder value.”

On October 9, Daniel Salinas, of Broken Arrow Oklahoma and Eric Horton, of San Diego California, were appointed to the board of directors, following the resignations of Russell Ward and Jeffory A. Carlson, and Mr. Carlson was appointed chief financial officer of Medtainer.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.